This study is completed in the United States, in Brazil, in Germany, .... It is testing ziprasidone for schizophrenia.
SchizophreniaDrugFrom 18 Years to 55 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether ziprasidone may be useful for adolescents experiencing schizophrenia.
What would participation involve?
Participants may receive ziprasidone, attend study visits with the research team. The registry lists locations in Brazil, in Germany, and in Greece.
Who is it mainly for?
This study appears to be mainly for adolescents with schizophrenia. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateNovember 2006
Recruitment status
Completed
Enrollment listed in the registry
255
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States, Brazil, Germany, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT00406315
Official title
A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00406315. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Brazil · 3 sites
Pfizer Investigational Site
Aparecida de Goiânia, Goiás
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro
Site status: Not listed — confirm with the team
Pfizer Investigational Site
São Paulo, São Paulo
Site status: Not listed — confirm with the team
Germany · 4 sites
Pfizer Investigational Site
Berlin
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Düsseldorf
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Hamburg
Site status: Not listed — confirm with the team
Pfizer Investigational Site
München
Site status: Not listed — confirm with the team
Greece · 2 sites
Pfizer Investigational Site
Athens
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Thessaloniki
Site status: Not listed — confirm with the team
Spain · 1 site
Pfizer Investigational Site
Zamora
Site status: Not listed — confirm with the team
Türkiye · 2 sites
Pfizer Investigational Site
Ankara
Site status: Not listed — confirm with the team
Pfizer Investigational Site
İzmit
Site status: Not listed — confirm with the team
United States · 28 sites
Pfizer Investigational Site
Phoenix, Arizona
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Costa Mesa, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Garden Grove, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
National City, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Orange, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
San Diego, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Temecula, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Torrance, California
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Hialeah, Florida
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Miami, Florida
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Miami, Florida
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Chicago, Illinois
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Des Plaines, Illinois
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Oakbrook Terrace, Illinois
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Schaumburg, Illinois
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Topeka, Kansas
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Olive Branch, Mississippi
Site status: Not listed — confirm with the team
Pfizer Investigational Site
St Louis, Missouri
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Nashua, New Hampshire
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Olean, New York
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Staten Island, New York
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Memphis, Tennessee
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Memphis, Tennessee
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Dallas, Texas
Site status: Not listed — confirm with the team
Pfizer Investigational Site
DeSoto, Texas
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Bothell, Washington
Site status: Not listed — confirm with the team
Pfizer Investigational Site
Kirkland, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving ziprasidone. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
